Edesa Biotech's Paridiprubart Shows Promise in Inhibiting Inflammation from Influenza and Other Pathogens

Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study demonstrated that inflammation signaling from multiple pathogens, including Influenza A, coronavirus, and a common bacterium (H. influenzae), was inhibited by Edesa's TLR4 antagonist, paridiprubart. These findings support ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity

ZyVersa Therapeutics, a clinical stage specialty biopharmaceutical company, has announced the publication of an article in Clinical Immunology that demonstrates the association between renal NLRP3 inflammasome activation and lupus nephritis disease activity. Lupus nephritis is characterized by inflammation in the kidney, protein leakage into the urine, and progressive kidney damage. The study fo..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

Merck's efinopegdutide has received FDA Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH), and Merck has released Phase IIa study results comparing efinopegdutide to Novo Nordisk's semaglutide. The new NAFLD data will be presented at the upcoming European Association for the Study of the Liver annual congress, and Merck plans to use both this data and the Fast Trac..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms